David E Coutant

5PUBLICATIONS
22CO-AUTHORS
PharmacogenomicsPredictive and prognostic markersBiologically active moleculesClinical pharmacology and therapeuticsNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 03, 2026
Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

|Apr 05, 2025
A novel physiologically-based pharmacokinetic model to estimate reduced CYP3A4 activity in cancer patients utilizing the neutrophil-to-lymphocyte ratio as an inflammatory marker.

David E Coutant, Jessica Rehmel, Donna M Edwards

|Dec 18, 2024
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.

Kyle W Sloop, Amy L Cox, David B Wainscott

|Jan 31, 2024
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.

Amita Datta-Mannan, Arie Regev, David E Coutant

|Dec 08, 2022
Therapeutic Protein Drug Interactions: A White Paper From the International Consortium for Innovation and Quality in Pharmaceutical Development.

David E Coutant, David W Boulton, Upendra P Dahal

Pageof 1

Frequent Collaborators

1 joint publications

Hilmar Schiller

1 joint publications

Amita Datta-Mannan

1 joint publications

Spencer Jones

1 joint publications

Kyle W Sloop